Related Experiment Videos
[Hypercoagulation aggravates renal dysfunction in patient with diabetic nephropathy]
1Department of Nephrology, First Affilliated Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou 510080, China.
Insights
Hypercoagulation, or increased blood clotting, contributes to kidney dysfunction in patients with diabetic nephropathy. Warfarin treatment improved clotting and slowed kidney function decline in a study of diabetic patients.
Area of Science:
- Nephrology
- Diabetology
- Hematology
Background:
- Diabetic nephropathy (DN) is a significant complication of diabetes, often associated with renal dysfunction.
- Hypercoagulation, an increased tendency for blood to clot, is increasingly recognized as a factor in various disease states.
Purpose of the Study:
- To investigate the relationship between hypercoagulation and the progression of renal dysfunction in patients with diabetic nephropathy.
- To assess the potential therapeutic effect of warfarin on coagulation status and renal function in this patient group.
Main Methods:
- Forty-six patients with type II diabetes and nephrotic syndrome were categorized into high, middle, and low creatinine clearance groups.
- Coagulation and fibrolysis parameters, alongside renal function, were evaluated.
- A subset of 14 patients received warfarin therapy.
Main Results:
- Patients with moderate to severe renal dysfunction exhibited higher coagulation activity compared to those with mild dysfunction.
- Warfarin administration led to significant improvements in coagulation and fibrolysis.
- Warfarin therapy appeared to delay the progression of renal dysfunction in patients with DN.
Conclusions:
- Hypercoagulation is identified as a contributing factor to renal dysfunction in patients with diabetic nephropathy.
- Targeting hypercoagulation may be a viable strategy to manage or slow the progression of kidney disease in DN patients.
Objective:
To investigate the relationship of hypercoagulation and renal dysfunction in patients with diabetic nephropathy(DN).
Methods:
Forty six diabetes type II patients with nephrotic syndrome were divided into 3 groups according to 24 hr creatinine clearance (Ccr) as high, middle and low groups. Fourteen of the 46 patients received warfarin therapy. The parameters of coagulation and fibrolysis as well as renal function were examined.
Results:
Patients with moderate and major renal dysfunction (M group and L group) displayed higher activities of coagulation than those with mild renal dysfunction (H group) did. Warfarin could obviously improve the status of coagulation and fibrolysis in patients with DN and delay the progress of renal dysfunction.
Conclusion:
Hypercoa-gulation was one of the causes of renal dysfunction in patients with DN.